Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Overview
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
Antengene Corp
Asa BioSciences LLC
Astex Pharmaceuticals Inc
BioMed Valley Discoveries Inc
Eli Lilly and Co
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Shanghai Green Valley Pharmaceutical Co Ltd
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Drug Profiles
ASN-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTX-029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JSI-287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KO-947 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3214996 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sprifermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulixertinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Dormant Products
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Discontinued Products
Mitogen Activated Protein Kise 3 (ERT2 or Insulin Stimulated MAP2 Kise or Extracellular Sigl Regulated Kise 1 or MAP Kise Isoform p44 or Microtubule Associated Protein 2 Kise or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: Asa BioSciences to present phase 1 clinical safety and efficacy data of oral, once-weekly, ASN007, a novel ERK 1/2 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 08, 2019: EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification
May 15, 2019: Eli Lilly presents update on ERK inhibitor, LY3214996 at ASCO 2019
Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress
Apr 10, 2018: Asa BioSciences Announces Presentations of ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting
Apr 09, 2018: Kura Oncology Presents Poster on KO-947 at AACR Annual Meeting 2018
Feb 22, 2018: Phase I Clinical Trial Shows Promise as Investigatiol Drug for Melanoma
Jan 03, 2018: Asa BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
Dec 15, 2017: First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors
Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
Oct 24, 2017: Asa BioSciences to Present Update On Lead Molecule ASN-007 at AACR-NCI-EORTC Intertiol Conference on Molecular Targets and Cancer Therapeutics
Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting
Oct 03, 2017: First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
Jun 21, 2017: NovellusDx Announced the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries’ BVD523
May 26, 2017: BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Antengene Corp, H2 2019
Pipeline by Asana BioSciences LLC, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BioMed Valley Discoveries Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Kalyra Pharmaceuticals Inc, H2 2019
Pipeline by Kura Oncology Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Shanghai Green Valley Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019